Cargando…

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy

Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bova, Maria, Valerieva, Anna, Wu, Maddalena Alessandra, Senter, Riccardo, Perego, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815761/ https://www.ncbi.nlm.nih.gov/pubmed/31695331 http://dx.doi.org/10.2147/DDDT.S192475

Ejemplares similares

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability
por: Diaz-Menindez, Maximiliano, et al.
Publicado: (2023)

The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews
por: Jean-Baptiste, Milenka, et al.
Publicado: (2022)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE)
por: Parsopoulou, Faidra, et al.
Publicado: (2022)

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012)

Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
por: Tyson, Christopher, et al.
Publicado: (2019)

Hereditary angioedema (HAE) in Belgium: results from a national survey
por: Van der Poorten, MM, et al.
Publicado: (2023)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

A patient with hereditary angioedema (HAE) with normal C1-INH and SLE with pregnancy
por: Taha, Omar S., et al.
Publicado: (2022)

Psychological processes in the experience of hereditary angioedema in adult patients: an observational study
por: Savarese, Livia, et al.
Publicado: (2021)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan
por: Zanichelli, Andrea, et al.
Publicado: (2015)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study
por: Hirose, Tomoya, et al.
Publicado: (2017)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial
por: Javaud, Nicolas, et al.
Publicado: (2016)

Therapeutic management of hereditary angioedema: past, present, and future
por: Valerieva, Anna, et al.
Publicado: (2021)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns
por: Nieto, Sandra, et al.
Publicado: (2023)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

83 Hereditary Angioedema and Normal C1-Inhibitor (HAE TYPE III): A Novel Mutation in the Coagulation Factor 12 Gene
por: Bork, Konrad, et al.
Publicado: (2012)

Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)
por: Palao-Ocharan, Paola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vcktrl4hr85brc8qdqj9vgn3vv